Results of Vical Inc.’s (VICL) SARS Vaccine Feature in Vaccine(1) Publication
In late 2002, an epidemic of severe acute respiratory syndrome SARS spread throughout the Guangdong Province of China. By 2003, the respiratory system and gastrointestinal tract disease had affected more than 8,000 and killed more than 900 people in 25 countries before it was brought under control. Today, biopharmaceutical companies are making advances for the prevention and treatment of diseases such as SARS through extensive research and development and DNA vaccines. Studies show that DNA vaccines have the potential to achieve desired response more quickly and cost effectively than conventional vaccines. Vical Incorporated (Nasdaq: VICL) researches and develops biopharmaceutical products…